Company: TBPH
Filing Date: 2025-04-10
Form Type: DEF 14A
Source: 0001104659-25-033819
Chunk: 48

Company: Theravance Biopharma, Inc.
Filing Date: 2025-04-10
Form: DEF 14A
Chunk 48
---
: $1,078,500; Mr. Sawaf: $449,374; and Mr. Grimaud: $449,374. (4) The amounts in this column reflect cash bonus awards earned by the named executive officers under our annual cash bonus plan, and which were paid in the first quarter of the following year. (5) Represents matching contributions for the 401(k) plan. (6) The executive officer was employed by us but was not one of our named executive officers in 2023. Accordingly, compensation information is only provided for 2024. Narrative Disclosure to Summary Compensation Table The compensation of our named executive officers generally consists of base salary, annual cash incentive opportunity and equity compensation. Our goal is to maintain a compensation program that will fairly compensate employees while attracting and retaining highly qualified employees, motivating their performance and rewarding the achievement of key corporate goals. We also aim to align employees’ long-term interests with those of our shareholders. We are a biopharmaceutical company that operates in an extremely competitive, rapidly changing and heavily regulated industry. We believe that the skill, talent, judgment and dedication of our executive officers

31

TABLE OF CONTENTS and other employees are critical factors affecting our shareholder value. Maximizing the value of our assets and delivering medicines to patients in need requires our executive officers to be expert in not only the science behind drug development, formulation and manufacturing, but also patient needs, prescriber concerns and priorities, institutional dynamics, the insurance reimbursement landscape, as well as the priorities, plans, strengths and weaknesses of our competitors and potential partners. To ensure we remain competitive in the market to hire and retain employees, our Chief Executive Officer and compensation committee frequently review data about the compensation of similar officers at companies within a peer group established by the compensation committee, with the advice of our compensation consultant. With our small team and a focus on executing our board of directors’ vision for long-term and short-term value creation and the development of medicines that make a difference in the lives of patients, we achieved the following in 2024: • YUPELRI Net Sales Growth . In 2024, YUPELRI experienced net sales growth and reached launch-to-date highs in annual net sales and brand profitability. Through the combined commercialization efforts with our partner Viatris Inc. (“Viatris”), total YUPELRI net sales increased by 8% to $238.6 million in 2024 compared to 2023. Hospital volumes, which we are directly responsible